This impressive benefit was consistent across the subgroup stratification factors, including histological tumor type (leiomyosarcoma vs non-leiomyosarcoma), quantity of previous treatments, and PDGFR expression. in the Accelerated Authorization Program by

S. currently unable to tolerate the side effects of cancer drug regimens. retinoic acid (ATRA) is an effective differentiation agent in acute promyelocytic leukemia (APL), but its effects are limited